Companies: 10,795·Total market cap: $144.5T
Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

SUPNNASDAQHealthcare● Active
$44.48
$-0.27(-0.60%)
Market Cap$2.6B
P/E Ratio
52W High$59.68
52W Low$30.83

Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

supn · stock forecast · 14 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 14 Wall Street analysts in the past 3 months

SellBuy

Buy

14 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
9
Hold
5
Sell
0
Strong Sell
0
Total: 14 · Buy rate: 64.3%

12-Month Price Target

High

$65.00

Consensus

$60.00

+34.9% upside

Low

$55.00

Median: $60 · Last Close: $44.48

The Supernus Pharmaceuticals, Inc. (SUPN) analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month SUPN price target is $60.00, representing +34.9% upside from the current price of $44.48.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $60 (34.9%)

Consensus Target

$60.00

34.9% upside

High Target

$65

46.1%

Low Target

$55

23.7%

Current Price

$44.48

as of today

Based on analyst price targets, the SUPN stock price prediction for the next 12 months ranges from $55 to $65. The consensus SUPN price forecast of $60.00 implies 34.9% upside from the current price of $44.48.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-10$42.624.19%

1-day model range: $42.46–$42.77. Peak: $42.77 (-4.19%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$57+28.3%
2028$67+50.1%
2029$74+65.4%
2030$78+75.6%
2031+82.0%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

14%0%86%
2Buy
0Neutral
12Sell
RSI (14)29.1Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · SUPN · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$44.41BUY
MA 10$45.42SELL
MA 20$47.42SELL
MA 50$49.06SELL
MA 100$50.05SELL
MA 200$49.00SELL
Current $SUPN · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$44.74SELL
EMA 10$45.49SELL
EMA 20$46.75SELL
EMA 50$48.44SELL
EMA 100$48.92SELL
EMA 200$47.24SELL
Current $SUPN · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Stifel2025-12-19
Maintains
HoldHold
TD Cowen2025-10-23
Maintains
BuyBuy
Piper Sandler2025-10-09
Upgrade ↑
NeutralOverweight
Cantor Fitzgerald2025-09-30
Maintains
OverweightOverweight
Piper Sandler2025-08-29
Maintains
NeutralNeutral
Cantor Fitzgerald2025-08-06
Maintains
OverweightOverweight
Cantor Fitzgerald2025-02-26
Maintains
NeutralNeutral
Cantor Fitzgerald2025-02-19
Downgrade ↓
OverweightNeutral
Piper Sandler2024-09-11
Downgrade ↓
OverweightNeutral
Piper Sandler2024-02-28
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on Supernus Pharmaceuticals, Inc. (SUPN) stock. Of the recent 61 rating actions, 11 were upgrades and 13 were downgrades. 14 analysts currently cover SUPN.

Analyst Recommendation Trends

Buy ratings00
Hold ratings11
Sell ratings00

SUPN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$867M

↓ 25.8% YoY

Revenue Next Year

$1.0B

↑ 17.6% YoY

EPS This Year

$2.49

EPS Next Year

$3.92

↑ 57.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast SUPN EPS of $2.49 for the current fiscal year, based on estimates from 2 analysts. The SUPN revenue forecast is $867M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The SUPN stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SUPN price target is $60.00 (+34.9% upside), with an analyst consensus of Buy.

The SUPN short-term stock prediction for tomorrow is $42.62 (-4.19%). The SUPN stock price prediction for 2027 estimates an average of $57. The SUPN stock prediction for 2030 projects a range of $75–$81.

Supernus Pharmaceuticals, Inc. trades on NASDAQ under the ticker SUPN. The SUPN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 64% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

SUPN forecast · 8 questions

According to 14 Wall Street analysts, the average 12-month SUPN price target is $60.00, with a high forecast of $65.00 and a low of $55.00. The median price target is shown in the chart above when available. This implies +34.9% potential upside from the current price of $44.48.

SUPN price targetWhat is SUPN price targetSUPN analyst price targetSUPN 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.